Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.33 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | DNM1L | O00429 | 1/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3010484 | 0.93 | THRB (0.42) | LMNAL3MBTL1THRBERBB2EPHA2 | |
| SCHEMBL3016262 | 0.92 | HTR2A (0.36) | L3MBTL1ADAMTS5KITHTR2AHTR2C | |
| SCHEMBL3016660 | 0.91 | GBA1 (0.38) | LMNAL3MBTL1THRBARDNM1L | |
| SCHEMBL3017117 | 0.91 | MAPT (0.38) | LMNAL3MBTL1ARHTR2AHTR2C | |
| SCHEMBL3013801 | 0.91 | L3MBTL1 (0.39) | LMNAL3MBTL1THRBERBB2EPHA2 | |
| SCHEMBL3001978 | 0.90 | VCAM1 (0.39) | LMNA | |
| SCHEMBL3012962 | 0.90 | AOC3 (0.34) | LMNAADAMTS5KITHTR2AHTR2C | |
| SCHEMBL3016706 | 0.90 | MAPT (0.37) | LMNAHTR2AHTR2C | |
| SCHEMBL3015155 | 0.89 | HTR2A (0.41) | LMNAL3MBTL1ARHTR2AHTR2C | |
| SCHEMBL3011356 | 0.89 | MAPT (0.39) | LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | SMN1; SMN2, HTT, SNCA | LMNA 80/4885L3MBTL1 1847/4885THRB 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.